GLP-1 Agonist Weight Loss Significantly Impacts Aesthetic Breast Surgery Outcomes

The use of GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) has surged, leading to substantial and rapid weight loss in patients with obesity and type 2 diabetes. This profound body composition change, particularly in the breast region, presents new challenges and considerations for plastic and reconstructive surgeons. This review addresses the critical need for updated surgical planning and patient counseling strategies for individuals undergoing aesthetic breast surgery after significant GLP-1-induced weight loss.

Patients on GLP-1 receptor agonists typically achieve 10-25% total body weight loss, with some studies reporting up to 22.5% reduction in body weight. This significant weight reduction often leads to substantial changes in breast volume and skin elasticity, impacting surgical planning and outcomes. For patients undergoing reduction mammoplasty, pre-operative weight loss can reduce the amount of tissue needing removal by up to 30%, potentially altering the surgical approach. Conversely, for mastopexy or augmentation, pre-existing skin laxity due to weight loss may necessitate more extensive skin resection or different implant choices in over 60% of cases. Surgeons should anticipate increased skin laxity and potential for volume depletion, requiring tailored surgical approaches to achieve optimal results. The most critical finding is the recommendation to delay aesthetic breast surgery for at least 6-12 months after a patient's weight has stabilized post-GLP-1 initiation, to ensure optimal and durable results and minimize the need for revision surgeries.